Long COVID in autoimmune rheumatic diseases
Y Fedorchenko, O Zimba - Rheumatology International, 2023 - Springer
Abstract Consequences of Corona Virus Disease-19 (COVID-19) in patients with rheumatic
diseases (RDs) are clinically diverse. SARS-CoV-2 infection has been associated with …
diseases (RDs) are clinically diverse. SARS-CoV-2 infection has been associated with …
The use of COVID-19 vaccines in patients with SLE
W Tang, Y Gartshteyn, E Ricker, S Inzerillo… - Current rheumatology …, 2021 - Springer
Abstract Purpose of Review Three COVID-19 vaccines obtained emergency authorization
from the Food and Drug Administration (FDA) and are widely used in the USA …
from the Food and Drug Administration (FDA) and are widely used in the USA …
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Background We describe the early experiences of adults with systemic rheumatic disease
who received the COVID-19 vaccine. Methods From 2 April to 30 April 2021, we conducted …
who received the COVID-19 vaccine. Methods From 2 April to 30 April 2021, we conducted …
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
The immune response to SARS-CoV-2 messenger RNA (mRNA) vaccines in patients with
rheumatic and musculoskeletal diseases (RMD) is undefined because these individuals …
rheumatic and musculoskeletal diseases (RMD) is undefined because these individuals …
Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two‐dose SARS–CoV‐2 messenger RNA vaccination
Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in
patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV …
patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV …
COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey
P Gaur, H Agrawat, A Shukla - Rheumatology international, 2021 - Springer
Patients with a systemic autoimmune rheumatic disease (AIRD) are vulnerable to SARS Cov-
2 infection. Vaccination against this infection can prevent the patients from developing …
2 infection. Vaccination against this infection can prevent the patients from developing …
Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
E Seyahi, G Bakhdiyarli, M Oztas, MA Kuskucu… - Rheumatology …, 2021 - Springer
Objective To assess antibody response to inactivated COVID-19 vaccine in patients with
immune-mediated diseases (IMD) among hospital workers and people aged 65 and older …
immune-mediated diseases (IMD) among hospital workers and people aged 65 and older …
Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine
FR Spinelli, EG Favalli, C Garufi, M Cornalba… - Arthritis research & …, 2022 - Springer
Background Little is known about the safety of SARS-CoV-2 vaccination in patients with
rheumatic musculoskeletal disease (RMD). We evaluated the occurrence of adverse events …
rheumatic musculoskeletal disease (RMD). We evaluated the occurrence of adverse events …
Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus
E Zavala-Flores, J Salcedo-Matienzo… - Clinical …, 2022 - Springer
The objective of this study is to identify post SARS-CoV-2 vaccine BNT162b2 (BioNTech &
Pfizer) side effects in patients with systemic lupus erythematosus (SLE) at the Cayetano …
Pfizer) side effects in patients with systemic lupus erythematosus (SLE) at the Cayetano …
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
The safety of the SARS-CoV-2 mRNA vaccines in patients with rheumatic and
musculoskeletal diseases (RMD) on immunomodulatory therapy is unknown because these …
musculoskeletal diseases (RMD) on immunomodulatory therapy is unknown because these …